地尔硫治疗左室射血分数保留型心力衰竭的临床疗效研究

doi:10.3969/j.issn.1002-1949.2019.02.013

Chinese Journal of Critical Care Medicine

2019, Vol. 39

Issue (2): 161-164 DOI: 10.3969/j.issn.1002-1949.2019.02.013

Assessment of diltiazem in heart failure with preserved left ventricular ejection fraction patients

Li Bin, Kang Ai-ling, Shen Jie, Chen De-chang

Shanghai Jiading Anting Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 201805, China

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (481 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effectiveness of diltiazem in heart failure with preserved ejection fraction (HF-PEF) patients. Methods The study involved 87 subjects diagnosed with HF-PEF. They were randomly divided into two group: 42 subjects assigned into control group, received traditional anti-heart failure optimal medical therapy; 47 subjects assigned into treatment group, not only received traditional optimal medical therapy but also diltiazem therapy. The New York Heart Association (NYHA) functional class and six-minute walking test (6MWT) and B-type natriuretic peptide (BNP) were recorded, ratio of mitral velocity to early diastolic velocity of the mitral annulus were detected by echocardiogram before and after treatment. The treatment lasted three months. Results The total effective rate （62.22%vs.47.62%）in treatment group was higher than it in control group, while 6MWT(m:520.63±62.41 vs. 223.64±23.47） and E/E' (8.28±4.92 vs. 10.28±5.21) and BNP (pg/mL:223.64±23.47 vs.170.36±21.39) in treatment group after treatment improved significantly than those in control group. There was statistically significant difference (P<0.05). Conclusion Diltiazem could improve the symptoms and cardiac diastolic function in HF-PEF.

Key words： Preserved ejection fraction Heart failure Diltiazem

Corresponding Authors: Chen De-chang, E-mail: 18918520002@189.cn

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Bin
	Kang Ai-ling
	Shen Jie
	Chen De-chang

Cite this article:

Li Bin,Kang Ai-ling,Shen Jie, et al. Assessment of diltiazem in heart failure with preserved left ventricular ejection fraction patients[J]. Chinese Journal of Critical Care Medicine, 2019, 39(2): 161-164.

URL:

http://www.cnemergency.org.cn/EN/10.3969/j.issn.1002-1949.2019.02.013 OR http://www.cnemergency.org.cn/EN/Y2019/V39/I2/161

［1］Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survivalof patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient date meta-analysis［J］. Eur Heart J, 2012, 33(14) : 1750-1757. ［2］中华医学会心脏病学分会.中国心力衰竭诊断及治疗指南［J］.中华心血管病杂志， 2014， 44（5）：1-5．［3］Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators［J］. JAMA, 1993, 270(14):1702-1707. ［4］Hillis GS, Mller JE, Pellikka PA, et al. Noninvasive estimation of left ventricular filling pressure by E/e′ is a powerful predictor of survival after acute myocardial infarction［J］. J Am Coll Cardiol, 2004, 43(3):360-367. ［5］Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy［J］. Circulation, 1999, 99(2):254-261. ［6］Ommen SR,Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures:A comparative simultaneous Doppler-catheterization study［J］. Circulation, 2000, 102 (15):1788-1794. ［7］Borlaug BA, Paulus WJ.Heart failure with preserved ejection fraction: pathophysiology，diagnosis， and treatment［J］. Eur Heart J, 2011, 32(6) : 670-679． ［8］Asrar ul Haq M, Wong C,Mutha V, et al. Therapeutic interventions for heart failure with preserved ejection fraction: a summary of current evidence［J］. World J Cardiol, 2014, 6(2) : 67-76． ［9］Bergstrm A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolicfunction.Results of the Swedish Doppler-echocardiographic study (SWEDIC)［J］. Eur J Heart Fail, 2004, 6(4) : 453-461．［10］Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction［J］. Am J Cardiol, 2004, 94(4) : 448-453． ［11］叶炳华，李爱云，朱晓燕.卡维地洛治疗舒张性心力衰竭临床观察［J］.中国心血管病研究杂志， 2005， 3(11) : 842-844. ［12］Yamamoto K, Origasa H, Hori M, et al. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)［J］. Eur J Heart Fail， 2013， 15(1) : 110-118. ［13］Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction［J］. N Engl J Med, 2008, 359(23):2456-2467. ［14］van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) ［J］. J Am Coll Cardiol, 2009, 53(23): 2150-2158. ［15］Conraads VM, Metra M, Kamp O, et al.Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity,and left ventricular function of patients with diastolic dysfunction:results of the ELANDD study［J］. Eur J Heart Fail, 2012, 14(2): 219-225.